On this page
17q12 deletion syndrome
This rare condition results from deletion of genetic material at position q12 on chromosome 17. Features typically include kidney abnormalities present from birth, developmental differences, and variable neurological involvement. Clinical severity varies considerably between affected individuals.
Overview
17q12 deletion syndrome arises when a portion of the long arm (q) of chromosome 17 is missing. This deletion encompasses multiple genes that are important for normal development of the kidneys, brain, and other organ systems. The condition was first recognised as a distinct clinical entity in the early 2000s when improved genetic testing methods allowed researchers to identify the common chromosomal region involved.
The deletion typically spans approximately 1.4 to 1.5 million base pairs of DNA and removes around 15 genes. Because multiple genes are lost simultaneously, affected individuals may experience a range of clinical features. The most consistent finding is kidney and urinary tract abnormalities, though the specific problems can differ substantially from one person to another. Some individuals have mild features that may go unrecognised until adulthood, whilst others have more significant medical needs from early life.
Exact prevalence figures are not well established, though the condition is considered rare. Many cases are identified through genetic testing performed to investigate kidney problems or developmental concerns in childhood. As awareness increases and genetic testing becomes more accessible through the NHS Genomic Medicine Service, additional affected individuals are being identified, including some adults who were not diagnosed during childhood.
Symptoms & clinical features
Clinical features of 17q12 deletion syndrome vary widely, even amongst family members who carry the same deletion. Kidney and urinary tract abnormalities are the most common finding, present in approximately half of affected individuals. These may include cystic kidneys (fluid-filled sacs within the kidney tissue), structural malformations of the kidneys, or abnormalities in how the ureters connect the kidneys to the bladder. Some individuals develop maturity-onset diabetes of the young (MODY), a form of diabetes that typically begins before age 25 years.
Developmental and neurological features occur in many cases. These may include delayed speech and language development, learning difficulties of variable severity, and autism spectrum characteristics. Some children experience low muscle tone in infancy, which can affect feeding and motor milestones. Behavioural differences such as anxiety, attention difficulties, or social communication challenges have been reported in research studies, though not all affected individuals experience these features.
Physical features tend to be subtle and non-specific. Some affected individuals have no distinctive facial characteristics, whilst others may have minor differences such as a slightly broad forehead or widely spaced eyes. Additional findings reported in some cases include seizures, vision problems, and structural brain differences visible on imaging scans. The combination and severity of features present in any individual cannot be reliably predicted from the size of the deletion alone.
Video: Genetics 101
Affected organs
The kidneys and urinary tract are the organ systems most frequently affected in 17q12 deletion syndrome. Kidney abnormalities range from mild structural differences that cause no symptoms to severe malformations that impair kidney function. Cystic kidney disease, where fluid-filled sacs develop within the kidney tissue, represents one pattern of involvement. In more severe cases, affected kidneys may not develop properly during foetal life, potentially leading to reduced kidney function that requires monitoring throughout childhood and adulthood.
The brain and nervous system are also commonly affected. Structural brain differences identified on MRI scans may include variations in the size or shape of certain brain regions, though these findings do not always correlate directly with the degree of learning or behavioural differences an individual experiences. The pancreas is involved in some cases, particularly the insulin-producing cells, which can lead to early-onset diabetes (MODY5). Other organ systems are generally less consistently affected, though isolated reports describe heart abnormalities, genital differences, and other findings in individual cases.
Risks & severity
Severity in 17q12 deletion syndrome spans a broad spectrum. Some affected individuals have significant kidney disease requiring specialist nephrology care from early childhood, whilst others have only mild kidney abnormalities detected incidentally on scans performed for other reasons. The degree of developmental and learning differences similarly varies from subtle language delays to more substantial intellectual disability requiring ongoing educational support.
Kidney function should be monitored throughout life in affected individuals, as some kidney abnormalities are progressive. The risk of developing diabetes, particularly MODY5, appears elevated compared to the general population, though precise risk figures have not been firmly established. Neurological features such as seizures occur in a subset of cases. Long-term outcomes depend largely on which organs are affected and to what degree, making individualised monitoring important. Family members who carry the same deletion may experience quite different clinical courses, reflecting additional genetic and environmental factors that influence how the deletion manifests.
Genetic causes
17q12 deletion syndrome results from loss of genetic material at chromosome position 17q12. Chromosomes are structures in each cell that carry genetic information, and humans typically have 23 pairs of chromosomes. Each chromosome has a short arm (p) and a long arm (q). The deletion in this syndrome affects the long arm of chromosome 17, specifically a region designated as q12.
The deleted segment contains approximately 15 genes. Loss of these genes simultaneously disrupts multiple developmental pathways. One gene of particular importance is HNF1B, which provides instructions for producing a protein that regulates gene activity in the kidneys, pancreas, and other organs during development. Loss of HNF1B function is thought to account for the kidney abnormalities and diabetes risk seen in affected individuals. Other genes within the deleted region likely contribute to neurological and developmental features, though research continues to clarify which specific genes are responsible for particular aspects of the clinical picture.
The deletion typically arises spontaneously (de novo) during formation of reproductive cells or early embryonic development, meaning it was not inherited from either parent. However, because the deletion is present in the affected individual's cells, it can potentially be passed to future children.
Inheritance pattern
Most cases of 17q12 deletion syndrome occur as new (de novo) events, meaning the deletion arose spontaneously and was not inherited from either parent. When this occurs, the parents' chromosomes are typically normal, and the chance of having another affected child is generally low, though not zero due to the theoretical possibility of germline mosaicism (where some of a parent's reproductive cells carry the deletion).
When an individual carries the 17q12 deletion, there is a 50% chance with each pregnancy of passing the deleted chromosome to a child. This follows an autosomal dominant inheritance pattern for transmission, though the term "chromosomal" inheritance is more precise since this involves loss of a chromosomal segment rather than a change in a single gene. Family members who inherit the same deletion may have quite different clinical features, a phenomenon called variable expressivity. Some relatives may have kidney problems whilst others primarily experience developmental differences, and severity can differ substantially even within the same family.
Diagnosis & testing
Diagnosis of 17q12 deletion syndrome is confirmed through genetic testing that can detect chromosomal deletions. Chromosomal microarray analysis (also called array comparative genomic hybridisation or array-CGH) is the most commonly used test, as it can identify deletions and duplications across all chromosomes. This test is available through the NHS for individuals with developmental differences, learning difficulties, autism spectrum features, or congenital kidney abnormalities, particularly when multiple features are present.
Referral for genetic testing typically comes through a paediatrician, clinical geneticist, or nephrologist when a child presents with suggestive features. In adults, the condition may be identified when genetic testing is performed to investigate kidney disease or diabetes of unclear cause. Some cases are identified prenatally when ultrasound scans detect kidney abnormalities in the developing foetus, prompting genetic testing. Genetic counselling is recommended alongside testing to help families understand what results mean for the affected individual and relatives. Within the NHS Genomic Medicine Service, regional genetic services coordinate testing and provide access to specialist genetic counsellors who can discuss implications for family planning and predictive testing for relatives.
Management & lifestyle
Management of 17q12 deletion syndrome focuses on monitoring and addressing the specific features present in each affected individual. Regular kidney function assessment is recommended, typically including blood tests to measure creatinine and other markers of kidney health, along with urine tests and periodic imaging scans to evaluate kidney structure. Individuals with significant kidney abnormalities may require care from a specialist nephrologist.
Screening for diabetes is advisable, particularly from adolescence onwards, given the elevated risk of MODY5 in this condition. Developmental support should be tailored to individual needs and may include speech and language therapy, educational support, and behavioural interventions where appropriate. Children with learning difficulties may benefit from an Education, Health and Care Plan to ensure appropriate support at school. Regular vision and hearing checks are sensible, as these can affect learning if problems go undetected. Genetic counselling provides families with information about recurrence risks and options for prenatal or preimplantation genetic diagnosis in future pregnancies. Involvement of multiple specialists is often needed, coordinated through paediatric or adult medicine services depending on the individual's age.
UK care pathway
Within the NHS, individuals suspected of having 17q12 deletion syndrome may be referred to regional clinical genetics services for assessment and genetic testing. Chromosomal microarray testing is available through the NHS Genomic Medicine Service for patients meeting clinical criteria, which typically include congenital kidney abnormalities, developmental delay, or features suggestive of a chromosomal disorder. Referrals may come from paediatricians, nephrologists, or general practitioners.
Once a diagnosis is confirmed, ongoing care involves multiple specialties depending on which organ systems are affected. Paediatric nephrology services monitor kidney function and structure, whilst endocrinology input may be needed for diabetes management. Developmental paediatricians or community child health teams can coordinate support for learning and behavioural needs. Genetic counsellors, accessible through regional genetics centres, provide information about inheritance and testing options for family members. Adults with the condition may transition to adult nephrology and diabetes services as appropriate. Coordination between specialists helps ensure comprehensive monitoring tailored to individual clinical needs.
Frequently asked questions
Will my child with 17q12 deletion syndrome need a kidney transplant?
Most individuals with 17q12 deletion syndrome do not require kidney transplantation. The severity of kidney involvement varies considerably - some have mild structural differences that cause no functional impairment, whilst others have more significant abnormalities requiring monitoring. Your child's nephrologist can assess kidney function and discuss long-term outlook based on individual findings.
Can other family members have the deletion without knowing?
This is possible, as the condition shows variable expressivity - relatives with the same deletion may have different, sometimes subtle, features. If your child's deletion occurred spontaneously rather than being inherited, other family members are unlikely to carry it. Genetic counsellors can arrange testing for relatives if appropriate and discuss implications.
What support is available for developmental and learning difficulties?
Support depends on individual needs and may include speech and language therapy, educational support at school, and occupational therapy. Your GP or paediatrician can refer to appropriate local services. Many children benefit from an Education, Health and Care Plan, which ensures coordinated support across health, education, and social care settings.
How often should kidney function be monitored?
Monitoring frequency varies based on severity of kidney involvement. Your nephrologist or paediatrician will recommend an appropriate schedule, which might range from annual checks for mild abnormalities to more frequent monitoring if kidney function is impaired. Regular assessment helps detect any changes early so interventions can be considered if needed.
References
- Bhargav VSLV, Venkatachari M, Arun Babu T. 17q12 microdeletion syndrome. BMJ case reports. 2024. PMID: 39510608
- Ceravolo G, Mollica S, Cavallaro M. 17q12 Recurrent Deletion Syndrome in Childhood. Genes. 2025. PMID: 41465172
- Warren EB, Briano JA, Ellegood J. 17q12 deletion syndrome mouse model shows defects in craniofacial, brain and kidney development, and glucose homeostasis. Disease models & mechanisms. 2022. PMID: 36373506
- Hasegawa Y, Takahashi Y, Nagasawa K. Japanese 17q12 Deletion Syndrome with Complex Clinical Manifestations. Internal medicine (Tokyo, Japan). 2024. PMID: 38432894
- Roehlen N, Hilger H, Stock F. 17q12 Deletion Syndrome as a Rare Cause for Diabetes Mellitus Type MODY5. The Journal of clinical endocrinology and metabolism. 2018. PMID: 30032214
- Rasmussen M, Vestergaard EM, Graakjaer J. 17q12 deletion and duplication syndrome in Denmark-A clinical cohort of 38 patients and review of the literature. American journal of medical genetics. Part A. 2016. PMID: 27409573
- Cohen JL, Crowley TB, McGinn DE. 22q and two: 22q11.2 deletion syndrome and coexisting conditions. American journal of medical genetics. Part A. 2018. PMID: 30244528
- Bulu E, Kalayci Yigin A, Agirbasli D. Co-existing bipolar disease and 17q12 deletion: a rare case report. Psychiatric genetics. 2022. PMID: 34629388